Üks Life4me+ peamiseid eesmärke on uute HIVi- ja muude sugulisel teel levivate nakkuste juhtumite, nagu ka C-hepatiiti ja tuberkuloosi nakatumise ennetamine.

Nutirakendus aitab luua kontakti arstide ja HIV positiivsete inimeste vahel. Nutirakendus aitab mugavalt organiseerida ravimite võtmise aegu, seadistada ainult Teile arusaadavad ja personaalseid meeldetuletusi, võimaldab saada arstilt tagasisidet ning panna aega vastuvõtule või analüüsidele.

Kõik uudised / September 2018

Arhiiv

✕

26 september 2018

6638

Immunotherapy of HIV passed the first phase of clinical trials

Immunotherapy of HIV passed the first phase of clinical trials

Preliminary results from phase I clinical trials demonstrated the safety and tolerability of cell therapy, including the introduction of artificially expanded T-cells with widely neutralizing antibodies (bNAbs) into the blood of HIV-positive volunteers who had previously ...

25 september 2018

7199

American patients with hepatitis C will be available branded generics Gilead

American patients with hepatitis C will be available branded generics Gilead

On Monday, September 24, the American biopharmaceutical company Gilead Sciences Inc. said that it expects to launch in the US the production of a number of analogues for its own products. Among the applicants for the release are generic drugs for the treatment of hepatitis ...

24 september 2018

6527

The number of heterosexuals with HIV in Australia is growing - experts

The number of heterosexuals with HIV in Australia is growing - experts

According to the latest statistics published today by the Kirby Institute (University of New South Wales, Australia), the number of diagnoses of "HIV infection" among Australian heterosexual men over the past five years has increased by 10%. The study showed that more than ...

18 september 2018

6454

Scientists: HIV should be considered a major risk factor for cardiovascular disease

Scientists: HIV should be considered a major risk factor for cardiovascular disease

People living with HIV are twice as likely to suffer from cardiovascular disease (CVD), the results of a meta-analysis published in Circulation magazine show. According to researchers, over the past 20 years, the number of CVDs associated with HIV has tripled. Today this ...

17 september 2018

7046

EMA will consider an application for the registration of an antiviral drug dolutegravir / lamivudine

EMA will consider an application for the registration of an antiviral drug dolutegravir / lamivudine

September 14 became known that the pharmaceutical company ViiV Healthcare, part of the GlaxoSmithKline structure, applied to the European Medicines Agency (EMA) for the registration of a two-component antiretroviral dolutegravir / lamivudine intended for the treatment of ...

17 september 2018

8707

HIV-positive Norwegians may not get modern antiretroviral drugs

HIV-positive Norwegians may not get modern antiretroviral drugs

The Kingdom of Norway, which has maintained the status of the state with the world's highest human development index (HDI) for the last ten years and is the third largest on the planet by nominal GDP per capita, is on the verge of a crisis of underfunding the drug people ...

17 september 2018

6492

ViiV submits two-drug regimen for HIV in Europe

ViiV submits two-drug regimen for HIV in Europe

#ViiV Healthcare has submitted an application in Europe for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.

3 september 2018

6679

Early birth and weight loss: why Africa refuses dolutegravir?

Early birth and weight loss: why Africa refuses dolutegravir?

Antiretroviral regimens (ART) based on protease inhibitors or nucleoside reverse transcriptase inhibitors can cause early childbirth and low birth weight. This is reported by Aidsmap with reference to the Journal of Acquired Immune Deficiency Syndromes.